- Home
- FRMI vs LEGN Comparison
FRMI vs LEGN Comparison
Compare FRMI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FRMI | LEGN |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.9B |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FRMI | LEGN |
|---|---|---|
| Price | $9.76 | $22.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $30.86 | ★ $69.33 |
| AVG Volume (30 Days) | ★ 7.5M | 2.1M |
| Earning Date | 05-12-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $909,045,000.00 |
| Revenue This Year | N/A | $68.52 |
| Revenue Next Year | N/A | $48.63 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $7.28 | $20.21 |
| 52 Week High | $36.99 | $45.30 |
Technical Indicators
Market Signals| Indicator | FRMI | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 43.37 |
| Support Level | N/A | $20.21 |
| Resistance Level | N/A | $24.12 |
| Average True Range (ATR) | 0.00 | 1.04 |
| MACD | 0.00 | 0.37 |
| Stochastic Oscillator | 0.00 | 52.43 |
Price Performance
Historical ComparisonAbout FRMI Fermi Inc.
Fermi Inc is an energy and hyperscaler development company purpose-built for the AI era. Its Project Matador, a multi-gigawatt energy and data center development campus designed to support the accelerating needs of to-be-built AI infrastructure. Through its REIT structure, Fermi offers investors exposure to AI infrastructure growth and long-term, large-scale and reliable energy development in a tax-efficient public vehicle.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.